2024-12-25 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

The cumulative return for JNJ is 24.68%, significantly underperforming the S&P 500 (VOO) which had a cumulative return of 120.69%.  The provided data shows a large divergence (-96.0), placing JNJ at the 2.6th percentile of its historical performance relative to the S&P 500.  This indicates JNJ's substantial underperformance compared to the broader market over the analyzed period.  The alpha consistently shows negative values suggesting underperformance relative to the market benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $145.85
* **5-Day Moving Average:** $144.78
* **20-Day Moving Average:** $148.70
* **60-Day Moving Average:** $154.81

The current price is below all three moving averages, suggesting a potential downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 35.21 - Suggests the stock is currently in oversold territory.
* **PPO (Price Oscillator):** -0.04 - Indicates a bearish momentum.
* **Recent Relative Divergence:** -0.1 - Shows a recent short-term downward trend.
* **Expected Return:** 0.0% - The provided data suggests no significant outperformance relative to the S&P 500 is expected over the long term (2+ years) based on current analysis.  The low current valuation may present opportunity for long-term investors, however, this should be considered in conjunction with broader market outlook and the company's fundamental performance.


**4. Recent Earnings Analysis:**

The provided data shows some volatility in EPS and relatively flat revenue growth over the past few quarters:

* **Revenue:** Revenue has remained relatively stable around $21-22.5B over the past five quarters.  Growth is marginal.
* **EPS:** EPS has fluctuated significantly. The unusually high EPS in Q3 2023 (10.32) stands out and requires further investigation to determine if it represents a genuine increase in profitability or a one-off event (e.g., accounting adjustments).  Otherwise, EPS shows overall relative decline.  There is no indication of earnings beat/miss versus expectations.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue growth is minimal. Profit margins are relatively stable, hovering around 69%, however, this requires further investigation due to the volatility in the EPS data.

* **Capital and Profitability:** Equity has remained largely consistent, yet the ROE experienced extreme volatility and has shown a sharp decrease across the latest reported quarters.  The extraordinarily high ROE of 36.54% in Q3 2023 should be investigated further.


**6. News and Recent Issues:**

No specific news or analyst opinions are provided within the given data.  Information on recent market outlook and analyst opinions would be necessary to provide a complete analysis.  The extreme volatility in reported EPS and ROE values require further investigation to fully understand the company's recent performance.


**7. Overall Analysis:**

JNJ is currently underperforming the S&P 500 significantly. Technical indicators suggest the stock is oversold, but the underlying financial performance shows considerable volatility and relative underperformance, particularly in EPS and ROE.  The exceptionally high values observed in Q3 2023 for both EPS and ROE necessitate additional data and investigation to determine the validity of these reported numbers and their overall impact on the firm's performance.  Further investigation into the reasons behind the recent EPS and ROE volatility and the lack of revenue growth is crucial.  The analysis provided is limited due to missing context such as analyst expectations, market conditions, and the causes behind the volatile earnings numbers.   More comprehensive data on recent news, analyst reports, and macroeconomic factors are necessary to provide a thorough evaluation and outlook.


**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Investing involves risk, and past performance is not indicative of future results.  Always conduct your own thorough research and consult with a financial advisor before making any investment decisions.
